Mass Immunization Device
Search text
About 24 results
(0.09 seconds)
University of Pittsburgh researchers have developed a novel approach to augment VEGF therapy for ischemic tissue revascularization using epigenetic principles. Researchers identified that hyperglycemia leads to DNA methylation-based silencing of the PLCγ2 gene, hindering VEGF therapy. Using a CRISPR/dCas9-based demethylation cocktail delivered via tissue nano-transfection (TNT) technology, the PLCγ2 promoter is specifically demethylated in endothelial cells during VEGF therapy.
• Diabetic Wound Healing: Promotes the formation of new blood vessels to improve tissue perfusion and accelerate healing. The University of Pittsburgh has developed a technology that enhances in vivo vasculogenic reprogramming using Tissue Nanotransfection (TNT) to deliver specific transcription factors. This innovative approach holds significant promise for diabetic wound healing and ischemic tissue regeneration.
The technology employs a resonance-based wireless power transfer system designed for implantable devices operating in freely moving subjects. On the receiver end, a compact composite coil—integrating two planar spiral sub-coils with one helical sub-coil—captures the magnetic fields, rectifies, and filters the energy to power the implanted device. - Ensures reliable and efficient power transfer to implantable devices even when they move freely.